This is an introductory paper by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development. The paper is based on the experiences we have encountered using valuation in actual negotiations with the various pitfalls that negotiators and valuation practitioners have while negotiating a deal.

This content is restricted to members. To view this content please register or login below to view this content.

Register to receive up-to-date information and advice on tax developments within your industry.